Clinical value of albumin-bilirubin grade in evaluating the prognosis of hepatocellular carcinoma
10.3969/j.issn.1001-5256.2019.07.040
- VernacularTitle:白蛋白-胆红素分级评估肝细胞癌预后的价值
- Author:
Hao LUO
1
;
Jun HUANG
Author Information
1. Department of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China)
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellular;
albumin-bilirubin grade;
prognosis
- From:
Journal of Clinical Hepatology
2019;35(7):1608-1612
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common primary malignant tumors in the world, and although there are various therapeutic methods for HCC, its prognosis remains unsatisfactory. Albumin-bilirubin (ALBI) grade is a new clinical index which can be used to evaluate liver function and prognosis of patients with HCC. This article reviews the advances in the application of ALBI grade in surgical treatment, local ablation, transarterial chemoembolization, and drug therapy for HCC. It is pointed out that ALBI grade has a good value in predicting the prognosis of HCC patients undergoing different therapies.
